Evidence map›Paper›PMID 40423659›Full record

ArticleChembiochem : a European journal of chemical biology2025

Synthesis and Evaluation of Trehalose-Based Mertansine Warheads for Bacillus Calmette-Guérin Delivery of Anticancer Agents.

Michael Grimmeisen, Xuan Wang, Melissa Weldle, Kerstin Sartory, Sara Benkhelifa, Yu Zhang, Trinh Dao, Jonas Meyer, Oliver Gorka, Olaf Groß and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Michael GrimmeisenUniversity of Freiburg, Institute of Organic Chemistry, Albertstrasse 21, 79104, Freiburg, Germany.
Xuan WangUniversity of Freiburg, Institute of Organic Chemistry, Albertstrasse 21, 79104, Freiburg, Germany.
Melissa WeldleUniversity of Freiburg, Institute of Organic Chemistry, Albertstrasse 21, 79104, Freiburg, Germany.
Kerstin SartoryUniversity of Freiburg, Institute of Organic Chemistry, Albertstrasse 21, 79104, Freiburg, Germany.
Sara BenkhelifaUniversity of Freiburg, Institute of Organic Chemistry, Albertstrasse 21, 79104, Freiburg, Germany.
Yu ZhangUniversity of Freiburg, Institute of Organic Chemistry, Albertstrasse 21, 79104, Freiburg, Germany.
Trinh DaoUniversity of Freiburg, Institute of Organic Chemistry, Albertstrasse 21, 79104, Freiburg, Germany.
Jonas MeyerUniversity of Freiburg, Institute of Organic Chemistry, Albertstrasse 21, 79104, Freiburg, Germany.
Oliver GorkaInstitute of Neuropathology, University of Freiburg, University Medical Center, Faculty of Medicine, Breisacher Straße 113, 79106, Freiburg, Germany.
Olaf GroßCIBSS-Centre for Integrative Biological Signalling Studies, University of Freiburg, Schänzlestrasse 18, 79104, Freiburg, Germany.
Claudia Jessen-TrefzerUniversity of Freiburg, Institute of Organic Chemistry, Albertstrasse 21, 79104, Freiburg, Germany.ORCID https://orcid.org/0000-0003-4216-8189

Funding

Deutsche ForschungsgemeinschaftInnovative Research Team of High-level Local University in Shanghai
6 · The paper itself

Abstract

Nonmuscle invasive bladder cancer (NMIBC) accounts for 75% of bladder cancer cases, with Bacillus Calmette-Guérin (BCG) immunotherapy as the gold standard for high-risk patients. BCG elicits a robust immune response but is limited by adverse effects and resistance. To enhance its efficacy, a trehalose-based conjugation strategy is developed, tethering a cytostatic agent to BCG via a cleavable disulfide linker. This system enables selective drug integration into the BCG envelope and controlled release in tumor cells, aiming to improve therapeutic precision while minimizing toxicity. This approach combines immunotherapy with targeted chemotherapy, offering a promising strategy for NMIBC treatment.

Indexed as

Antineoplastic AgentsBCG VaccineDrug Delivery SystemsTrehaloseUrinary Bladder NeoplasmsCell Line, TumorHumansAntineoplastic AgentsBCG VaccineTrehaloseanti cancer agentsantigen 85 complexbladder cancerdeliverymertansinemycobacteriatrehalose

Identifiers

PMID40423659
PMCPMC12432487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.